Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALNY
Nasdaq
2834
https://www.alnylam.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alnylam Pharmaceuticals, Inc.
Alnylam Issues 2023 Corporate Responsibility Report
- May 7th, 2024 12:00 pm
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
- May 5th, 2024 12:48 pm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
- May 3rd, 2024 5:01 pm
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
- May 3rd, 2024 4:29 pm
Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
- May 3rd, 2024 1:21 pm
Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
- May 3rd, 2024 7:11 am
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
- May 3rd, 2024 5:06 am
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
- May 2nd, 2024 2:00 pm
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
- May 2nd, 2024 1:10 pm
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
- May 2nd, 2024 12:00 pm
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
- May 1st, 2024 12:10 pm
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
- Apr 30th, 2024 1:15 pm
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
- Apr 30th, 2024 11:00 am
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Apr 25th, 2024 2:01 pm
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
- Apr 18th, 2024 12:00 pm
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
- Apr 8th, 2024 12:44 pm
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
- Apr 7th, 2024 12:00 pm
Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%
- Mar 29th, 2024 11:19 am
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
- Mar 20th, 2024 12:00 pm
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Scroll